The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL).
Wayne Su
Consultant or Advisory Role - Teva
Peter Quon
Consultant or Advisory Role - Teva
John Whalen
Consultant or Advisory Role - Teva
Research Funding - Teva
Gayatri Ranganathan
Consultant or Advisory Role - Teva
Samantha Wronski
Consultant or Advisory Role - Teva
Mkaya Mwamburi
Consultant or Advisory Role - United Biosource Corporation
Kevin B. Knopf
Consultant or Advisory Role - United Biosource Corporation
James A. Sterchele
Employment or Leadership Position - Teva
Christopher G. Salvador
Employment or Leadership Position - Teva
Ipek Ozer Stillman
Consultant or Advisory Role - Teva
Ananth Kadambi
Consultant or Advisory Role - Teva